Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 10/20 | 0.70 |
| ▸ | LTB4R2 | Q9NPC1 | 12/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673 | 0.91 | AGTR1 (0.58) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2969136 | 0.91 | AGTR1 (0.58) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2118 | 0.89 | AGTR1 (0.55) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2789 | 0.88 | AGTR1 (0.55) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL3138 | 0.88 | AGTR1 (0.55) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL9429098 | 0.87 | LTB4R2 (0.54) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL28456750 | 0.87 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL3042 | 0.87 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2969141 | 0.87 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL6683646 | 0.87 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | claimed |
| WO-2020039394-A1 | NEW DRUG COMBINATIONS | NOVARTIS AG (CH) | 2020-02-27 | — | — | WO | disclosed |
| US-20200016109-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS AG (CH) | 2020-01-16 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2067470-A1 | Pharmaceutical compositions containing valsartan and process for its preparation | Laboratorios Lesvi, S.L. (ES) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008148599-A2 | PROCESS FOR OBTAINING A VALSARTAN SALT USEFUL FOR OBTAINING VALSARTAN | INKE, S.A. (ES) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007085399-A1 | USE OF A COMBINATION OF VALSARTAN AND A CALCIUM CHANNEL BLOCKER IN THE TREATMENT OF INSUFFICIENT BLOOD FLOW AND CEREBRAL FUNCTIONAL DISORDERS | NOVARTIS AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1140071-B1 | USE OF AT-1 RECEPTOR ANTAGONIST OR AT-2 RECEPTOR MODULATOR FOR TREATING DISEASES ASSOCIATED WITH AN INCREASE OF AT-1 OR AT-2 RECEPTORS | NOVARTIS AG (CH) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005110480-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005030202-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR TREATING CEREBROVASCULAR DISORDERS | NOVARTIS AG (CH) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004101535-A1 | PHARMACEUTICAL COMPOSITION COMPRISING VALSARTAN | NOVARTIS AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR1 3252/4885LTB4R2 609/4885ABCB11 4659/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR1 8/4885LTB4R2 254/4885ABCB11 4566/4885 |
| US-20200016109-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 4/4885LTB4R2 1393/4885ABCB11 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.